CY1124088T1 - Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος - Google Patents

Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος

Info

Publication number
CY1124088T1
CY1124088T1 CY20211100363T CY211100363T CY1124088T1 CY 1124088 T1 CY1124088 T1 CY 1124088T1 CY 20211100363 T CY20211100363 T CY 20211100363T CY 211100363 T CY211100363 T CY 211100363T CY 1124088 T1 CY1124088 T1 CY 1124088T1
Authority
CY
Cyprus
Prior art keywords
treatment
nervous system
central nervous
system disorders
thiazolidinedione derivatives
Prior art date
Application number
CY20211100363T
Other languages
English (en)
Inventor
Ana María GARCÍA COLLAZO
David John Augustus ECKLAND
Maria Pilar Pizcueta Lalanza
Marc Martinell Pedemonte
Original Assignee
Minoryx Therapeutics S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S.L. filed Critical Minoryx Therapeutics S.L.
Publication of CY1124088T1 publication Critical patent/CY1124088T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει 5-(4-(2-(5-(1-υδροξυαιθύλ) πυριδίνη-2-ύλ) αιθόξυ) βενζύλ) θειαζολιδίνο-2,4-διόνη και καινοτόμα στερεοϊσομερή της εν λόγω ένωσης για χρήση στη θεραπεία διαταραχών του κεντρικού νευρικού συστήματος (ΚΝΣ).
CY20211100363T 2014-04-02 2021-04-27 Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος CY1124088T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP15713499.0A EP3125888B1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
CY1124088T1 true CY1124088T1 (el) 2022-05-27

Family

ID=50513194

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100765T CY1120454T1 (el) 2014-04-02 2018-07-23 Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
CY20211100363T CY1124088T1 (el) 2014-04-02 2021-04-27 Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100765T CY1120454T1 (el) 2014-04-02 2018-07-23 Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος

Country Status (24)

Country Link
US (3) US9782395B2 (el)
EP (2) EP3125888B1 (el)
JP (2) JP6745726B2 (el)
KR (1) KR102418167B1 (el)
CN (1) CN106470991B (el)
AU (1) AU2015239112C1 (el)
CA (1) CA2943373C (el)
CL (1) CL2016002508A1 (el)
CY (2) CY1120454T1 (el)
DK (2) DK3388064T3 (el)
EA (2) EA035866B1 (el)
ES (2) ES2678046T3 (el)
HR (2) HRP20180983T1 (el)
HU (2) HUE039555T2 (el)
IL (1) IL248037B (el)
LT (2) LT3125888T (el)
MX (1) MX2016012687A (el)
NZ (1) NZ725492A (el)
PL (2) PL3125888T3 (el)
PT (2) PT3388064T (el)
SG (1) SG11201608218QA (el)
SI (2) SI3125888T1 (el)
WO (1) WO2015150476A1 (el)
ZA (1) ZA201607286B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2015239112C1 (en) * 2014-04-02 2020-08-20 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
PL3548026T3 (pl) * 2016-12-01 2021-08-23 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby
MX2019007327A (es) * 2016-12-23 2019-09-02 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
BR112020024939A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]benzil]-1,3-tiazolidina-2,4-diona e seus sais
EP3801515A1 (en) * 2018-06-06 2021-04-14 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CN112512524A (zh) * 2018-06-06 2021-03-16 米尼奥尔克斯治疗有限公司 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法
MX2022013021A (es) 2020-04-30 2023-01-16 Minoryx Therapeutics S L Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
ES2161692T3 (es) * 1991-04-11 2001-12-16 Upjohn Co Derivados de tiazolidindiona, produccion y uso de los mismos.
AU4104593A (en) * 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
DE60209824T2 (de) 2001-12-21 2006-10-19 Smithkline Beecham Corp. Dosierschema für ppar-gamma-aktivatoren
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
WO2005016339A1 (en) * 2003-07-24 2005-02-24 Case Western Reserve University Methods for the treatment of parkinson's disease
ES2397944T3 (es) * 2006-03-16 2013-03-12 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
PL2512470T3 (pl) * 2009-12-15 2017-06-30 Octeta Therapeutics, Llc Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2015239112C1 (en) * 2014-04-02 2020-08-20 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Also Published As

Publication number Publication date
WO2015150476A1 (en) 2015-10-08
PT3125888T (pt) 2018-07-20
US10179126B2 (en) 2019-01-15
US20180133202A1 (en) 2018-05-17
EP3388064B1 (en) 2021-03-10
HUE039555T2 (hu) 2019-01-28
MX2016012687A (es) 2017-04-27
LT3125888T (lt) 2018-07-10
EP3125888A1 (en) 2017-02-08
HUE055351T2 (hu) 2022-05-28
AU2015239112A1 (en) 2016-11-10
CA2943373C (en) 2023-01-10
ES2678046T3 (es) 2018-08-08
HRP20180983T1 (hr) 2018-08-10
JP2020117539A (ja) 2020-08-06
IL248037B (en) 2020-09-30
NZ725492A (en) 2023-06-30
JP2017511339A (ja) 2017-04-20
CN106470991A (zh) 2017-03-01
BR112016022974A2 (pt) 2017-12-26
EP3125888B1 (en) 2018-05-23
SI3125888T1 (en) 2018-08-31
CN106470991B (zh) 2020-07-31
EA202091120A2 (ru) 2020-08-31
ES2872335T3 (es) 2021-11-02
LT3388064T (lt) 2021-05-25
ZA201607286B (en) 2021-07-28
JP6745726B2 (ja) 2020-08-26
KR20160145639A (ko) 2016-12-20
EA035866B1 (ru) 2020-08-21
IL248037A0 (en) 2016-11-30
SG11201608218QA (en) 2016-10-28
EA201691997A1 (ru) 2017-02-28
US20160235729A1 (en) 2016-08-18
PT3388064T (pt) 2021-05-14
SI3388064T1 (sl) 2021-08-31
PL3125888T3 (pl) 2018-09-28
PL3388064T3 (pl) 2021-07-19
KR102418167B1 (ko) 2022-07-08
CY1120454T1 (el) 2019-07-10
CL2016002508A1 (es) 2017-04-21
DK3125888T3 (en) 2018-06-25
EA202091120A3 (ru) 2020-12-30
HRP20210518T1 (hr) 2021-05-14
EP3388064A1 (en) 2018-10-17
DK3388064T3 (da) 2021-04-19
AU2015239112C1 (en) 2020-08-20
CA2943373A1 (en) 2015-10-08
AU2015239112B2 (en) 2020-05-07
US20190255032A1 (en) 2019-08-22
US9782395B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
EA202092441A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201790271A1 (ru) Ингибиторы гликозидазы
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX367918B (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
EA201592212A1 (ru) Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
DK3672975T3 (da) Kondenserede, heterocykliske derivater som bcl-2-hæmmere til behandling af neoplastiske sygdomme
CL2021000044A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)
EA201171063A1 (ru) Фармацевтические составы олмесартана
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EA201990400A1 (ru) Соединения и композиции и их применение
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
HK1255438A1 (zh) 用於治療癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯並呋喃-2-基)甲基)丙烯酰胺
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
NZ630803A (en) Optically active pde10 inhibitor
PL3154939T3 (pl) Sposób syntezy 2-(2,5-dimetylo-1h-pirol-1-ilo)-1,3-propanodiolu i jego podstawionych pochodnych
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
EP3541801A4 (en) 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
DK3288949T3 (da) Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
PH12017500123A1 (en) Crystal of azole benzene derivative
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EA201990320A1 (ru) Кристаллические формы 4-циано-n-(2-(4,4-диметилциклогекс-1-ен-1-ил)-6-(2,2,6,6-тетраметилтетрагидро-2h-пиран-4-ил)пиридин-3-ил)-1h-имидазол-2-карбоксамида